MedWatch

Lundbeck handed massive fine

The European Commission has ruled that agreements between Danish company Lundbeck and four generics manufacturers violated European competition law and has therefore handed the company a massive fine – the largest ever of its kind involving a Danish company. Lundbeck calls it disappointing and intends to appeal the decision.

Foto: Lundbeck/PR

It was a violation of European competition law when Lundbeck made deals with four generics manufacturers concerning its antidepressant citalopram, the European Commission has decided according to a press release from the Danish company, which also reveals Lundbeck’s intentions to appeal the decision.

“We are surprised and disappointed that the EU commission has reached this erroneous conclusion, which we totally disagree with, and it is therefore our intention to appeal,” says Ulf Wiinberg, CEO of Lundbeck.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Genmab-partner trækker sig fra samarbejde

Abbvie ønsker ikke længere at udvikle en fælles kræftkandidat med Genmab, men biotekselskabet skal stadig betale royalites af et eventuelt fremtidigt salg ved kommercialisering.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier